Protirelin

Intravenous
Assessment of thyroid function and TSH reserve

Do not dilute solution.

Caution in patients with bronchial asthma or other types of obstructive airway disease, myocardial ischaemia, severe hypothyroidism. To reduce incidence of hypotension, Protirelin should be given while the patient is lying down. Breast enlargement and leakage of milk have been reported in lactating women.

Headache, lightheadedness, dizziness, nausea, stomach pain, strange taste, mouth dryness, urge to urinate, flushing, hypotension, transient increase in pulse rate and BP, rarely bronchospasm.

Symptoms of overdose have not been observed in patients receiving up to 1 mg of IV Protirelin.

Thyroid hormones, levodopa, phenothiazines, salicylates, bromocriptine, carbamazepine, lithium and pharmacological doses of corticosteroids may decrease TSH response to Protirelin. Increased TSH response may be observed when used with metoclopramide, amiodarone, theophyllines, and oestrogens use in men. May enhance response if overtreated with antithyroid drugs.

Description: Protirelin is a synthetic tripeptide hormone used as diagnostic test agent in assessing thyroid function and thyroid-stimulating hormone (TSH) reserve in the pituitary gland. It stimulates the release of TSH from the anterior pituitary gland, also causes concomitant rise in serum prolactin levels. It is used as diagnostic test for mild hyperthyroidism, ophthalmic Grave's disease, mild or preclinical hypothyroidism, hypopituitarism, and hypothalmic disease.
Pharmacokinetics:
Distribution: Rapidly disappears from plasma after admin. When given via IV inj in healthy subjects, serum levels peak at about 20 min after admin.
Excretion: Excreted in urine (about 5.5%; within 30 min). Elimination half-life: About 5.3 min.

Other Therapeutic Products